|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
WO1988007054A1
(en)
|
1987-03-18 |
1988-09-22 |
Research Corporation Limited |
Complement-binding peptide
|
|
GB8709290D0
(en)
|
1987-04-16 |
1987-05-20 |
Secretary Trade Ind Brit |
Precision motion slideways
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
WO1990006952A1
(fr)
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Facteur de stimulation de colonies de granulocytes modifies chimiquement
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
ATE139258T1
(de)
|
1990-01-12 |
1996-06-15 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
AU8507191A
(en)
|
1990-08-29 |
1992-03-30 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
GB9022543D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
|
CA2103887C
(en)
|
1991-12-13 |
2005-08-30 |
Gary M. Studnicka |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
ATE381614T1
(de)
|
1992-07-24 |
2008-01-15 |
Amgen Fremont Inc |
Bildung von xenogenen antikörpern
|
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
|
US6091001A
(en)
|
1995-03-29 |
2000-07-18 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
AU5632296A
(en)
|
1995-04-27 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
AUPN568095A0
(en)
|
1995-09-27 |
1995-10-26 |
Austin Research Institute, The |
Anti-Galalpha(1,3)Gal antibody binding peptides
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
CA2275141A1
(en)
*
|
1996-10-29 |
1998-05-07 |
Thomas Spies |
Cell stress regulated human mhc class i gene
|
|
EP2305027B1
(en)
|
1996-12-03 |
2014-07-02 |
Amgen Fremont Inc. |
Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US5830698A
(en)
|
1997-03-14 |
1998-11-03 |
Idec Pharmaceuticals Corporation |
Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
|
|
CA2290485C
(en)
|
1997-05-21 |
2008-08-05 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL220113B1
(pl)
|
1999-01-15 |
2015-08-31 |
Genentech Inc |
Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
|
|
EP2278003B2
(en)
|
1999-04-09 |
2020-08-05 |
Kyowa Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US20090175821A1
(en)
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
|
US6475220B1
(en)
|
1999-10-15 |
2002-11-05 |
Whiteside Biomechanics, Inc. |
Spinal cable system
|
|
US7091321B2
(en)
|
2000-02-11 |
2006-08-15 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US6725230B2
(en)
|
2000-07-18 |
2004-04-20 |
Aegis Analytical Corporation |
System, method and computer program for assembling process data of multi-database origins using a hierarchical display
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
WO2002068615A2
(en)
|
2001-02-28 |
2002-09-06 |
Fred Hutchinson Cancer Research Center, Inc. |
Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives
|
|
US20040115198A1
(en)
|
2001-02-28 |
2004-06-17 |
Fred Hutchinson Cancer Research Center |
Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
|
|
US6566208B2
(en)
|
2001-07-25 |
2003-05-20 |
Chartered Semiconductor Manufacturing Ltd. |
Method to form elevated source/drain using poly spacer
|
|
US7084257B2
(en)
*
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
|
JP2005532253A
(ja)
|
2001-10-25 |
2005-10-27 |
ジェネンテック・インコーポレーテッド |
糖タンパク質組成物
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20040110226A1
(en)
|
2002-03-01 |
2004-06-10 |
Xencor |
Antibody optimization
|
|
ATE394674T1
(de)
|
2002-04-22 |
2008-05-15 |
Univ Florida |
Funktionalisierte nanopartikel und verwendungsverfahren
|
|
EP1578923A4
(en)
*
|
2002-04-22 |
2009-01-21 |
Hutchinson Fred Cancer Res |
SOLUBLE MIC POLYPEPTIDES AS MARKERS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASES OR CONDITIONS
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
EP2298805A3
(en)
|
2002-09-27 |
2011-04-13 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
US7666417B2
(en)
|
2003-04-22 |
2010-02-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for treating autoimmune diseases or conditions
|
|
US20100069614A1
(en)
*
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
JP4808614B2
(ja)
|
2003-06-27 |
2011-11-02 |
アムジエン・フレモント・インコーポレイテツド |
上皮成長因子受容体の欠失型変異体を認識する抗体、およびそれらの使用
|
|
US7871610B2
(en)
*
|
2003-08-12 |
2011-01-18 |
Dyax Corp. |
Antibodies to Tie1 ectodomain
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
ES2645026T3
(es)
*
|
2004-04-05 |
2017-12-01 |
The Regents Of The University Of California |
Anticuerpos de NKG2D para su uso en el tratamiento de artritis reumatoide o enfermedad de Crohn
|
|
CN101001873B
(zh)
|
2004-08-04 |
2013-03-13 |
曼璀克生物科技有限责任公司 |
Fc区变体
|
|
CN101495513B
(zh)
*
|
2004-10-19 |
2014-08-06 |
安姆根有限公司 |
促血管生成素-2特异性结合剂
|
|
EP1812062B1
(en)
|
2004-10-25 |
2022-03-09 |
Merck Sharp & Dohme Corp. |
Anti-addl antibodies and uses thereof
|
|
US20080148432A1
(en)
*
|
2005-12-21 |
2008-06-19 |
Mark Scott Abad |
Transgenic plants with enhanced agronomic traits
|
|
CN101128483B
(zh)
*
|
2004-12-21 |
2015-06-03 |
阿斯利康公司 |
血管生成素-2的抗体及其应用
|
|
NZ601439A
(en)
|
2005-06-08 |
2012-11-30 |
Brigham & Womens Hospital |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
|
|
US8232297B2
(en)
*
|
2005-09-21 |
2012-07-31 |
4Sc Ag |
Sulphonylpyrroles as inhibitors of HDACs novel sulphonylpyrroles
|
|
WO2007055926A1
(en)
|
2005-11-03 |
2007-05-18 |
Fred Hutchinson Cancer Research Center |
Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells
|
|
US8248965B2
(en)
|
2005-11-03 |
2012-08-21 |
Motorola Solutions, Inc. |
Method and apparatus regarding use of a service convergence fabric
|
|
AU2006324477A1
(en)
*
|
2005-12-15 |
2007-06-21 |
Medimmune Limited |
Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
|
|
DE102006009847A1
(de)
|
2006-03-01 |
2007-09-06 |
Sweredjuk, Robert, Dr. |
Verfahren von Absorbieren von Schadstoffen und Gerüchen
|
|
JP5745221B2
(ja)
|
2006-08-07 |
2015-07-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
タンパク質マトリックスワクチンおよびそのようなワクチンの製造方法および投与方法
|
|
US20110060120A1
(en)
|
2006-09-08 |
2011-03-10 |
Obeid Michel Sarkis |
Immunogenic treatment of cancer by peptides inducing the plasma membrane exposure of erp57
|
|
EP2083857A4
(en)
|
2006-09-22 |
2010-03-24 |
Dana Farber Cancer Res Inc |
METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
|
|
US9492518B2
(en)
*
|
2006-10-04 |
2016-11-15 |
Dana-Farber Cancer Institute, Inc. |
Tumor immunity
|
|
EP1944611A1
(en)
*
|
2007-01-11 |
2008-07-16 |
Université de la Méditerranée |
Biomarker for the medicine and the biology of the reproduction
|
|
WO2008131406A2
(en)
|
2007-04-23 |
2008-10-30 |
Fred Hutchinson Cancer Research Center |
NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5
|
|
AU2008254951A1
(en)
*
|
2007-05-14 |
2008-11-27 |
Biogen Idec Ma Inc. |
Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
|
|
AU2009215188B2
(en)
|
2008-02-13 |
2014-09-18 |
Dana-Farber Cancer Institute, Inc. |
Continuous cell programming devices
|
|
WO2011063336A2
(en)
|
2009-11-20 |
2011-05-26 |
President And Fellows Of Harvard College |
Secondary site of antigen stimulation for therapeutic vaccination
|
|
US9370558B2
(en)
|
2008-02-13 |
2016-06-21 |
President And Fellows Of Harvard College |
Controlled delivery of TLR agonists in structural polymeric devices
|
|
JO2913B1
(en)
*
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
WO2010011242A2
(en)
*
|
2008-03-24 |
2010-01-28 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnoisis of systemic anthrax infection
|
|
US8182809B1
(en)
|
2008-09-08 |
2012-05-22 |
University Of Washington |
Methods for treating cancer by inhibiting MIC shedding
|
|
US8133979B2
(en)
|
2008-12-16 |
2012-03-13 |
Hoffmann-La Roche Inc. |
Antibodies against human angiopoietin 2
|
|
US8207497B2
(en)
|
2009-05-08 |
2012-06-26 |
Ionsense, Inc. |
Sampling of confined spaces
|
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
|
KR101688522B1
(ko)
|
2009-12-15 |
2016-12-21 |
삼성전자주식회사 |
안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
|
|
US8796420B2
(en)
|
2009-12-31 |
2014-08-05 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
|
WO2011097603A1
(en)
*
|
2010-02-08 |
2011-08-11 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
US8753640B2
(en)
|
2011-05-31 |
2014-06-17 |
University Of Washington Through Its Center For Commercialization |
MIC-binding antibodies and methods of use thereof
|
|
CN102911270A
(zh)
*
|
2011-08-05 |
2013-02-06 |
浙江大学 |
一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法
|
|
SI2760471T1
(sl)
|
2011-09-30 |
2017-04-26 |
Dana-Farber Cancer Institute, Inc. |
Terapevtski peptidi
|
|
CA2862101A1
(en)
*
|
2012-02-07 |
2013-08-15 |
Innate Pharma |
Mica binding agents
|
|
KR20150130462A
(ko)
|
2013-03-15 |
2015-11-23 |
다나-파버 캔서 인스티튜트 인크. |
치료 펩티드
|
|
WO2014157322A1
(ja)
|
2013-03-28 |
2014-10-02 |
本田技研工業株式会社 |
報知システム、電子装置、報知方法、およびプログラム
|
|
US9572898B2
(en)
|
2013-09-09 |
2017-02-21 |
Seton Hall University |
Functionalized fluorine containing phthalocyanine molecules
|
|
KR20160090904A
(ko)
|
2013-12-06 |
2016-08-01 |
다나-파버 캔서 인스티튜트 인크. |
치료 펩티드
|
|
CA2939006A1
(en)
|
2014-03-14 |
2015-09-17 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
|
US20170198054A1
(en)
|
2014-05-21 |
2017-07-13 |
Dana-Farber Cancer Institute |
Methods for treating cancer with anti bip or anti mica antibodies
|